TORONTO, July 2, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announced that Mr. John-Peter Bradford has resigned from the Board, effective June 27th, 2014.
Mr. Bradford has been retained by Biosign as a Consultant to the company and will be assisting the Company by providing advice to management and the board, as requested. Mr. Bradford said: "I wish Biosign well and look forward to helping the company to grow."
With this change, the Board now consists of Dr. Michael Gross (Chairman), Mr. Dennis Rygwalski (Chair of the Audit Committee), Mr. Brian Neill and Mr. Robert Kaul (Biosign CEO). The Company expects to replace Mr. Bradford on the Board in the near future.
Biosign Chairman Michael Gross stated: "We are sorry to lose the service, counsel and enthusiasm of John-Peter on our Board, but we are thrilled that he will continue to work with the Company in the capacity of Consultant. John-Peter has many years of experience in business particularly in territories that Biosign intends to operate in, such as the United States and the Middle East. The whole board looks forward to his continued counsel and enthusiasm as we execute our business plan."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave™ Health Monitor and the Healthanywhere™ Patient monitoring / self-care platform. The Company's various software solutions, including Clinicserver™ and PencilThat™ offer industry-leading allied health clinic and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information: Biosign Contact Information, Robert Kaul, Chief Executive Officer, Biosign Technologies, Phone: (416) 218-9800 ext. 201, Email: email@example.com